SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging. - 2Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- 3In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 4The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- 5CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- Knesset sets special panel to fast-track Karhi’s communications reform
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- What's your #1 tone
- Key Business Regulations to Consider While Arranging Your Independent venture
- What did the gov’t approve for Israel’s 2026 state budget?
- New dietary guidelines recommend more dairy, meat and fats: What to know
- 10 Moving Design Frill for Summer 2023
- Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market
- Civilian toll mounts in Iran as war presses on
